FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Reilly

Research Profile

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Henry J Pieniaszek; Anna F Davidson; Harry L Walton; Donald J P Pinto; Richard E Olson; Thomas M Reilly; Yu Chen Barrett
A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma.
H L Walton; MH Corjay; S N Mohamed; Shaker A Mousa; L D Santomenna; Thomas M Reilly
Hypoxia induces differential expression of the integrin receptors alpha(vbeta3) and alpha(vbeta5) in cultured human endothelial cells.
Adrienne L Racanelli; Sandra K Gibbs; K L Schlingmann; MH Corjay; Prabhakar K Jadhav; Thomas M Reilly
Inhibition of neointima formation by a nonpeptide alpha(v)beta(3) integrin receptor antagonist in a rabbit cuff model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Reilly (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: Henry J Pieniaszek; Anna F Davidson; Harry L Walton; Donald J P Pinto; Richard E Olson; Thomas M Reilly; Yu Chen Barrett
A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma.
Journal of pharmaceutical and biomedical analysis 2003;30(5):1441-9.
2000: H L Walton; MH Corjay; S N Mohamed; Shaker A Mousa; L D Santomenna; Thomas M Reilly
Hypoxia induces differential expression of the integrin receptors alpha(vbeta3) and alpha(vbeta5) in cultured human endothelial cells.
Journal of cellular biochemistry 2000;78(4):674-80.
2000: Adrienne L Racanelli; Sandra K Gibbs; K L Schlingmann; MH Corjay; Prabhakar K Jadhav; Thomas M Reilly
Inhibition of neointima formation by a nonpeptide alpha(v)beta(3) integrin receptor antagonist in a rabbit cuff model.
Journal of cellular biochemistry 2000;77(2):213-20.
1999: Jeffrey S Barrett; J Yu; RP Kapil; P Padovani; F Brown; William Ebling; MH Corjay; Thomas M Reilly; Jeffrey M Bozarth; Shaker A Mousa; Henry J Pieniaszek
Disposition and exposure of the fibrinogen receptor antagonist XV459 on alphaIIBbeta3 binding sites in the guinea pig.
Biopharmaceutics & drug disposition 1999;20(6):309-18.
1999: Richard E Olson; Thais M Sielecki; John Wityak; Donald J P Pinto; Douglas G Batt; William E Frietze; J Liu; AE Tobin; Michael J Orwat; S V Di Meo; Gregory C Houghton; G K Lalka; Shaker A Mousa; Adrienne L Racanelli; E A Hausner; RP Kapil; S R Rabel; MJ Thoolen; Thomas M Reilly; PS Anderson; Ruth R Wexler
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
Journal of medicinal chemistry 1999;42(7):1178-92.
1999: Shaker A Mousa; W Lorelli; S Mohamed; Douglas G Batt; Prabhakar K Jadhav; Thomas M Reilly
Alphavbeta3 integrin binding affinity and specificity of SM256 in various species.
Journal of cardiovascular pharmacology 1999;33(4):641-6.
1998: Shaker A Mousa; Jeffrey M Bozarth; W Lorelli; Mark S Forsythe; MJ Thoolen; AM Slee; Thomas M Reilly; P A Friedman
Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1277-84.
1998: Shaker A Mousa; Richard E Olson; Jeffrey M Bozarth; W Lorelli; Mark S Forsythe; Adrienne L Racanelli; S Gibbs; K Schlingman; T Bozarth; RP Kapil; John Wityak; Thais M Sielecki; Ruth R Wexler; MJ Thoolen; AM Slee; Thomas M Reilly; PS Anderson; P A Friedman
Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
Journal of cardiovascular pharmacology 1998;32(2):169-76.
1996: Shaker A Mousa; Mark S Forsythe; W Lorelli; Jeffrey M Bozarth; Chu-Biao Xue; John Wityak; Thais M Sielecki; Richard E Olson; W DeGrado; R Kapil; M Hussain; Ruth R Wexler; MJ Thoolen; Thomas M Reilly
Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.
Coronary artery disease 1996;7(10):767-74.
1996: Shaker A Mousa; W F DeGrado; D X Mu; R P Kapil; Benedict R Lucchesi; Thomas M Reilly
Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
Circulation 1996;93(3):537-43.
1995: Thomas M Reilly; Shaker A Mousa; Adrienne L Racanelli; MJ Thoolen; S K Flint; Jeffrey M Bozarth; D X Mu; H L Walton
A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(12):2195-9.
1995: Y T Wachtfogel; C E Hack; J H Nuijens; Charles Kettner; Thomas M Reilly; Robert M Knabb; R Bischoff; H Tschesche; H Wenzel; Umberto Kucich
Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation.
The American journal of physiology 1995;268(3 Pt 2):H1352-7.
1994: S J McConnell; M L Kendall; Thomas M Reilly; R H Hoess
Constrained peptide libraries as a tool for finding mimotopes.
Gene 1994;151(1-2):115-8.
1994: Shaker A Mousa; Mark S Forsythe; M Diemer; Jeffrey M Bozarth; Thomas M Reilly
Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Coronary artery disease 1994;5(11):919-27.
1994: Shaker A Mousa; S Flint; W Lorelli; S Hassell; Jeffrey M Bozarth; W De Grado; Thomas M Reilly
Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs.
Thrombosis research 1994;76(2):109-19.
1994: A F Hajj-Ali; Thomas M Reilly; Pancras C Wong
Modulation of renal vasoconstrictor effect of NG-nitro-L-arginine in rabbit by angiotensin II and alpha-1 adrenergic receptor blockade.
The Journal of pharmacology and experimental therapeutics 1994;270(3):1152-7.
1994: T J Mitchell; Robert M Knabb; D D Christ; A R Farmer; Thomas M Reilly
Analysis of the thrombin inhibitor DuP 714 by an enzyme-linked immunosorbent assay.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1994;5(4):517-21.
1994: R H Hoess; A J Mack; H Walton; Thomas M Reilly
Identification of a structural epitope by using a peptide library displayed on filamentous bacteriophage.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(2):724-9.
1994: Thomas M Reilly; Shaker A Mousa; R Seetharam; Adrienne L Racanelli
Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1994;5(1):73-81.
1994: Shaker A Mousa; Jeffrey M Bozarth; Mark S Forsythe; P Tsao; L Pease; Thomas M Reilly
Role of platelet GpIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release.
Life sciences 1994;54(16):1155-62.
1993: Thomas M Reilly; Mark S Forsythe; Adrienne L Racanelli; S M Spitz; H L Walton; Shaker A Mousa
Recombinant plasminogen activator inhibitor-1 protects platelets against the inhibitory effects of plasmin.
Thrombosis research 1993;71(1):61-8.
1993: Shaker A Mousa; Thomas M Reilly
Pharmacological blockade of platelet GPIIb/IIIa and the inherited disorders of the platelet GPIIb/IIIa (Glanzmann's thrombasthenia): how safe is this antithrombotic approach for both acute and chronic treatment of thromboembolic disorders? Brief communication.
Cardiology 1993;83(1-2):36-7.
1993: Shaker A Mousa; Mark S Forsythe; Jeffrey M Bozarth; Thomas M Reilly
Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1.
Cardiology 1993;83(5-6):367-73.
1993: Shaker A Mousa; Jeffrey M Bozarth; Mark S Forsythe; W Lorelli; MJ Thoolen; N Ramachandran; S Jackson; W De Grado; Thomas M Reilly
Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist.
Cardiology 1993;83(5-6):374-82.
1992: Thomas M Reilly; Robert M Knabb; S M Hassell; Jeffrey M Bozarth; Mark S Forsythe; M C Mayo; Adrienne L Racanelli; Shaker A Mousa
Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1992;3(5):513-7.
1992: Thomas M Reilly; D D Christ; John V Duncia; S K Pierce; P B Timmermans
Monoclonal antibodies to the nonpeptide angiotensin II receptor antagonist, losartan.
European journal of pharmacology 1992;226(2):179-82.
1992: Adrienne L Racanelli; M J Diemer; A C Dobies; J R Dubin; Thomas M Reilly
Comparison of recombinant plasminogen activator inhibitor-1 and epsilon amino caproic acid in a hemorrhagic rabbit model.
Thrombosis and haemostasis 1992;67(6):692-6.
1992: Robert M Knabb; Charles Kettner; P B Timmermans; Thomas M Reilly
In vivo characterization of a new synthetic thrombin inhibitor.
Thrombosis and haemostasis 1992;67(1):56-9.
1991: A T Chiu; Shaker A Mousa; L J Pease; W A Roscoe; Jeffrey M Bozarth; Thomas M Reilly; R D Smith; P B Timmermans
Inhibition of the thrombin-platelet reactions by DuP 714.
Biochemical and biophysical research communications 1991;179(3):1500-8.
1991: A M Dwivedi; R W Woodeshick; H L Walton; Thomas M Reilly
A spectroscopic study of the conformations of active and latent forms of recombinant plasminogen activator inhibitor-1.
Biochemical and biophysical research communications 1991;175(2):437-43.
1990: W P Sisk; Gary Davis; D Kingsley; A T Chiu; Thomas M Reilly
High-level synthesis of biologically active human plasminogen activator inhibitor type 1 (PAI-1) in Escherichia coli.
Gene 1990;96(2):305-9.
1990: Pancras C Wong; Thomas M Reilly; P B Timmermans
Angiotensin II monoclonal antibody: blood pressure effects in normotensive and spontaneously hypertensive rats.
European journal of pharmacology 1990;186(2-3):353-6.
1990: Robert M Knabb; A T Chiu; Thomas M Reilly
Effects of recombinant plasminogen activator inhibitor type 1 on fibrinolysis in vitro and in vivo.
Thrombosis research 1990;59(2):309-17.
1990: Thomas M Reilly; R Seetharam; J L Duke; Gary Davis; S K Pierce; H L Walton; D Kingsley; W P Sisk
Purification and characterization of recombinant plasminogen activator inhibitor-1 from Escherichia coli.
The Journal of biological chemistry 1990;265(16):9570-4.
1989: Thomas M Reilly; G Greenplate; P B Timmermans
Tissue plasminogen activator-induced secretion of type-1 plasminogen activator inhibitor in cultured human fibroblasts.
Thrombosis research 1989;55(5):619-25.
1989: Pancras C Wong; W A Price; Thomas M Reilly; John V Duncia; P B Timmermans
Antihypertensive mechanism of captopril in renal hypertensive rats: studies with a nonpeptide angiotensin II receptor antagonist and an angiotensin II monoclonal antibody.
The Journal of pharmacology and experimental therapeutics 1989;250(2):515-22.
1989: Thomas M Reilly; Robert M Knabb; A T Chiu; D L Bradfute; P B Timmermans
Monoclonal antibodies to tissue-type plasminogen activator which prolong its clearance in vivo.
Thrombosis and haemostasis 1989;61(2):259-61.
1988: Thomas M Reilly; S K Flint; B G McHugh; K M Wilsbach-Volcheck; P B Timmermans
Characterization of a panel of monoclonal antibodies against human tissue-type plasminogen activator.
Hybridoma 1988;7(2):177-84.
1987: Thomas M Reilly; T J Mitchell; S K Flint; P B Timmermans
A monoclonal anti-idiotypic antibody which mimics angiotensin II in inducing a population of anti-hormone antibodies.
Hybridoma 1987;6(5):461-8.